Idera Pharmaceuticals (NASDAQ:IDRA) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRAGet Rating) in a research note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.

Shares of IDRA opened at $0.73 on Monday. Idera Pharmaceuticals has a one year low of $0.30 and a one year high of $1.71. The company has a 50-day simple moving average of $0.50 and a two-hundred day simple moving average of $0.55. The firm has a market capitalization of $38.67 million, a PE ratio of -1.74 and a beta of 1.50.

Idera Pharmaceuticals (NASDAQ:IDRAGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.08) EPS for the quarter.

Institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP grew its stake in shares of Idera Pharmaceuticals by 32.8% during the third quarter. Two Sigma Advisers LP now owns 795,871 shares of the biotechnology company’s stock valued at $820,000 after buying an additional 196,400 shares during the last quarter. Acadian Asset Management LLC increased its stake in Idera Pharmaceuticals by 27.6% in the 4th quarter. Acadian Asset Management LLC now owns 506,381 shares of the biotechnology company’s stock worth $287,000 after buying an additional 109,462 shares during the period. Geode Capital Management LLC increased its position in Idera Pharmaceuticals by 16.4% during the 3rd quarter. Geode Capital Management LLC now owns 373,483 shares of the biotechnology company’s stock valued at $384,000 after purchasing an additional 52,633 shares during the period. Renaissance Technologies LLC purchased a new position in Idera Pharmaceuticals during the 3rd quarter valued at about $280,000. Finally, Two Sigma Investments LP increased its position in Idera Pharmaceuticals by 202.3% during the 3rd quarter. Two Sigma Investments LP now owns 265,850 shares of the biotechnology company’s stock valued at $274,000 after purchasing an additional 177,900 shares during the period. Hedge funds and other institutional investors own 12.18% of the company’s stock.

About Idera Pharmaceuticals (Get Rating)

Idera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.